Peer-Reviewed Case Report Page 1 The VAD Journal: Review of 2019 Page 1 of 20 The VAD
Journal: The journal of mechanical assisted circulation and heart failure Editorial Review What …

More than 50% of heart failure (HF) patients require diuretic therapy after left ventricular
assist device (LVAD). Although few data related to diuretic response (DR) exist in stage D …

Tolvaptan is an effective therapy for heart failure patients with symptomatic congestion and
hyponatremia. The efficacy of its use in patients with continuous-flow left ventricular assist …

Heart failure is a significant global public health concern affecting millions of individuals.
Implantable Left Ventricular Assist Devices (LVADs) have proven beneficial for patients with …

Background: Both hypo-and hyperkalemia are associated with adverse events in heart
failure patients. Their effects on patients with left ventricular assist devices (LVADs) remains …

single-center study that the short-term use of tolvaptan following LVAD implantation is a safe
and effective therapy to augment diuresis and improve hyponatremia. Their analysis …

The survival rate in patients with advanced heart failure has improved owing to the
development of left ventricular assist devices (LVADs), which improves patients' …

There is a growing body of literature showing that left ventricular assist device (LVAD)
provides incomplete compensation of either left or right ventricular failure. 1 This explains …